Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.420
-0.010 (-0.29%)
At close: Dec 5, 2025, 4:00 PM EST
3.390
-0.030 (-0.88%)
After-hours: Dec 5, 2025, 5:44 PM EST
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$396,200
Profits / Employee
-$884,914
Market Cap
57.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATHE News
- 23 days ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewsWire
- 3 months ago - Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewsWire
- 4 months ago - Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - GlobeNewsWire